Rate My Professor Katherine Beck

Beck's research specializations encompass biological factors in treatment-resistant schizophrenia, glutamate system alterations using PET and MRI neuroimaging, and novel drugs targeting glutamate for psychotic disorders including schizophrenia and bipolar disorder. Key publications include 'Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis' (2017), 'Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis' (2018), 'Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis' (2020), 'Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis' (2023), 'Schizophrenia: from neurochemistry to circuits, symptoms and treatments' (2023), 'Histamine-3 Receptor Availability and Glutamate Levels in the Brain: A PET-1H-MRS Study of Patients With Schizophrenia and Healthy Controls' (2024), and 'New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction' (2024). Her 41 research outputs have accumulated over 3,000 citations. She has received major awards and fellowships from the Royal Society of Medicine, British Association of Psychopharmacology, European College of Neuropsychopharmacology, Schizophrenia International Research Society, and Royal College of Psychiatrists.